62 results
Page 2 of 4
8-K
EX-99.1
7ealp42g4
26 Aug 19
Bio-Path Announces Patient Dosing in Amended Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia
9:33pm
8-K
EX-99.1
81u7ax
6 Mar 19
Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia
4:30pm
8-K
EX-1.1
2kr nmq909o
16 Jan 19
Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock
5:25pm
8-K
EX-10.1
l1zd8fxg6sl3 880e
18 Apr 14
Entry into a Material Definitive Agreement
12:00am
424B5
rx8vfews xhon46
21 Jan 14
Prospectus supplement for primary offering
12:00am
424B5
up7jaapz
17 Jan 14
Prospectus supplement for primary offering
12:00am
8-K
EX-99.1
ym2jwdr5
3 Apr 12
Bio-Path Holdings Reports Fiscal Year 2011
12:00am
424B3
9xli6qhojvia3
30 Mar 12
Prospectus supplement
12:00am